Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for dialogue.

Genetics in medicine : official journal of the American College of Medical Genetics - 1 Sept 2009

Rubinstein Wendy S, Jiang Hongmei, Dellefave Lisa, Rademaker Alfred W

Abstract excerpt

PURPOSE: About half of unaffected BRCA1/2 carriers have a negative family history, confounding efforts toward presymptomatic carrier identification. Ovarian cancer is preventable for known carriers but is otherwise highly lethal. Cost-effectiveness and gains in life expectancy are important factors in evaluating the desirability of population-based genetic screening, currently the only viable strategy to identify...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cost-Benefit Analysis

Share to Genetic Counseling

Share to Incidence

Share to Life Expectancy

Share to Ovarian Neoplasms

Source

Identifiers

PMID: 19606050
DOI: 10.1097/GIM.0b013e3181afd322

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for dialogue.PMID 19606050Read ↗

Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.Semantic proximity Read ↗

Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women.Semantic proximity Read ↗

Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations.Semantic proximity Read ↗

Can population BRCA screening be applied in non-Ashkenazi Jewish populations? Experience in Macau population.Semantic proximity Read ↗

Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.Semantic proximity Read ↗

Preventing future cancers by testing women with ovarian cancer for BRCA mutations.Semantic proximity Read ↗

Population-based Genetic Testing for Precision Prevention.Semantic proximity Read ↗

A comparison of the detection of BRCA mutation carriers through the provision of Jewish population-based genetic testing compared with clinic-based genetic testingSemantic proximity Read ↗

Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening.Semantic proximity Read ↗

Population-based BRCA1/BRCA2 screening in Ashkenazi Jews: a call for evidence.Semantic proximity Read ↗

Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.Semantic proximity Read ↗

Population-Based BRCA1/2 Testing in Ashkenazi Jews: Ready for Prime Time.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.